{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:53:37Z","timestamp":1786121617113,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Istanbul University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Living kidney donation among carefully selected individuals is generally considered safe but post-donation health risks vary by factors including family history. Data on long-term outcomes of related living kidney donors of recipients with familial Mediterranean fever (FMFLRD) are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective multicenter study reviewed the medical records of living donors who donated between 2010 and 2021 across six transplantation centers. Cardiovascular and kidney outcomes were compared between 37\u00a0FMFLRD and a\u00a0propensity-matched control group of 74\u00a0donors to recipients without FMF (non-FMFLRD). Propensity score matching was based on donor age, sex, and follow-up time. Outcome measures included major cardiac events (MACE), new-onset hypertension, new-onset diabetes mellitus, proteinuria and estimated glomerular filtration rate (eGFR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The median follow-up duration of all donors was 4.0\u00a0years (interquartile range, IQR 2.0\u201311.0\u00a0years). The mean age of the FMFLRD group was 48.9\u202f\u00b1\u20099.3\u00a0years, The FMFLRD group showed a\u00a0significantly lower proportion of MACE (2.7% vs. 17.6%,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u20090.026) and new-onset hypertension (13.5% vs. 39.2%,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u20090.004) and a\u00a0trend towards a lower proportion of new-onset diabetes mellitus (2.7% vs. 14.9%,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u20090.052) compared to the non-FMFLRD group. There were no significant differences in long-term kidney function, as evidenced by similar eGFR and proteinuria levels between the groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The FMFLRD group showed similar kidney outcomes and lower rates of cardiovascular and metabolic complications during follow-up compared with matched non-FMFLRD; however, given the retrospective design and relatively short follow-up duration, long-term donor safety remains uncertain and the results should be interpreted cautiously.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00508-026-02764-2","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T05:53:39Z","timestamp":1786082019000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes of living related kidney donors of recipients with familial mediterranean fever-associated Amyloid A Amyloidosis"],"prefix":"10.1007","author":[{"given":"Ozgur Akin","family":"Oto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuba Elif","family":"Ozler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arzu","family":"Velioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilek Barutcu","family":"Atas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gizem","family":"Kumru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulmecit","family":"Yildiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sultan","family":"Ozkurt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabia Hacer","family":"Hocaoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yagmur","family":"Tahillioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muge","family":"Doksan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vefa","family":"Suleymanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ece","family":"\u00dck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeynep","family":"Celebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayse Serra","family":"Ucar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safak","family":"Mirioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet Burak","family":"Dirim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halil","family":"Yazici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista L.","family":"Lentine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasar","family":"Caliskan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"issue":"5","key":"2764_CR1","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1093\/ndt\/gfac335","volume":"38","author":"S Mirioglu","year":"2023","unstructured":"Mirioglu\u00a0S, Dirim\u00a0AB, Bektas\u00a0M, et\u00a0al. Efficacy and safety of interleukin\u20111 blockers in kidney transplant recipients with familial Mediterranean fever: a propensity score-matched cohort study. Nephrol Dial Transplant. 2023;38(5):1327\u201336.","journal-title":"Nephrol Dial Transplant"},{"key":"2764_CR2","doi-asserted-by":"crossref","unstructured":"Mirioglu S, Uludag O, Hurdogan O et\u00a0al. AA Amyloidosis: A\u00a0Contemporary View. Curr Rheumatol Rep 2024.","DOI":"10.1007\/s11926-024-01147-8"},{"issue":"23","key":"2764_CR3","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1056\/NEJMoa070265","volume":"356","author":"HJ Lachmann","year":"2007","unstructured":"Lachmann\u00a0HJ, Goodman\u00a0HJ, Gilbertson\u00a0JA, et\u00a0al. Natural history and outcome in systemic AA amyloidosis. N\u00a0Engl J Med. 2007;356(23):2361\u201371.","journal-title":"N Engl J Med"},{"issue":"12","key":"2764_CR4","doi-asserted-by":"publisher","first-page":"3458","DOI":"10.1681\/ASN.2006050460","volume":"17","author":"LM Dember","year":"2006","unstructured":"Dember\u00a0LM. Amyloidosis-associated kidney disease. J\u00a0Am Soc Nephrol. 2006;17(12):3458\u201371.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"2764_CR5","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00296-005-0074-3","volume":"26","author":"F Onen","year":"2006","unstructured":"Onen\u00a0F. Familial Mediterranean fever. Rheumatol Int. 2006;26(6):489\u201396.","journal-title":"Rheumatol Int"},{"key":"2764_CR6","unstructured":"Onen F, Sumer H, Turkay S et\u00a0al. Increased frequency of familial Mediterranean fever in Central Anatolia, Turkey. Clin Exp Rheumatol. 2004; 22(4)."},{"issue":"9103","key":"2764_CR7","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S0140-6736(97)09408-7","volume":"351","author":"E Ben-Chetrit","year":"1998","unstructured":"Ben-Chetrit\u00a0E, Levy\u00a0M. Familial Mediterranean fever. Lancet. 1998;351(9103):659\u201364.","journal-title":"Lancet"},{"issue":"11","key":"2764_CR8","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1111\/j.1600-6143.2011.03620.x","volume":"11","author":"T Kofman","year":"2011","unstructured":"Kofman\u00a0T, Grimbert\u00a0P, Canou\u00ef-Poitrine\u00a0F, et\u00a0al. Renal transplantation in patients with AA amyloidosis nephropathy: results from a French multicenter study. Am J Transplant. 2011;11(11):2423\u201331.","journal-title":"Am J Transplant"},{"issue":"8","key":"2764_CR9","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1097\/TP.0000000000003043","volume":"104","author":"I Sarihan","year":"2020","unstructured":"Sarihan\u00a0I, Caliskan\u00a0Y, Mirioglu\u00a0S, et\u00a0al. Amyloid A Amyloidosis After Renal Transplantation: An Important Cause of Mortality. Transplantation. 2020;104(8):1703\u201311.","journal-title":"Transplantation"},{"issue":"7","key":"2764_CR10","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/sj.ejhg.5200674","volume":"9","author":"E Yilmaz","year":"2001","unstructured":"Yilmaz\u00a0E, Ozen\u00a0S, Balci\u00a0B, et\u00a0al. Mutation frequency of Familial Mediterranean Fever and evidence for a high carrier rate in the Turkish population. Eur J Hum Genet. 2001;9(7):553\u20135.","journal-title":"Eur J Hum Genet"},{"key":"2764_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00716","volume":"11","author":"I Stoler","year":"2020","unstructured":"Stoler\u00a0I, Freytag\u00a0J, Orak\u00a0B, et\u00a0al. Gene-Dose Effect of MEFV Gain-of-Function Mutations Determines ex vivo Neutrophil Activation in Familial Mediterranean Fever. Front Immunol. 2020;11:716.","journal-title":"Front Immunol"},{"issue":"15","key":"2764_CR12","first-page":"3255","volume":"20","author":"A Balkarli","year":"2016","unstructured":"Balkarli\u00a0A, Akyol\u00a0M, Tepeli\u00a0E, et\u00a0al. MEFV gene variation R202Q is associated with metabolic syndrome. Eur Rev Med Pharmacol Sci. 2016;20(15):3255\u201361.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"6","key":"2764_CR13","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1093\/rheumatology\/kei279","volume":"45","author":"HJ Lachmann","year":"2006","unstructured":"Lachmann\u00a0HJ, Seng\u00fcl\u00a0B, Yavuz\u015fen\u00a0TU, et\u00a0al. Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatology (Oxford). 2006;45(6):746\u201350.","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"2764_CR14","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1007\/s00467-022-05430-7","volume":"37","author":"Y Caliskan","year":"2022","unstructured":"Caliskan\u00a0Y, Lentine\u00a0KL. Approach to genetic testing to optimize the safety of living donor transplantation in Alport syndrome spectrum. Pediatr Nephrol. 2022;37(9):1981\u201394.","journal-title":"Pediatr Nephrol"},{"issue":"2","key":"2764_CR15","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s40472-021-00340-3","volume":"9","author":"Y Caliskan","year":"2022","unstructured":"Caliskan\u00a0Y, Lee\u00a0B, Whelan\u00a0A, et\u00a0al. Evaluation of Genetic Kidney Diseases in Living Donor Kidney Transplantation: Towards Precision Genomic Medicine in Donor Risk Assessment. Curr Transplant Rep. 2022;9(2):127\u201342.","journal-title":"Curr Transplant Rep"},{"key":"2764_CR16","doi-asserted-by":"crossref","unstructured":"Caliskan Y, Lentine KL. Screening of Living Kidney Donors for Genetic Diseases: PRO. Kidney360. 2024.","DOI":"10.34067\/KID.0000000000000350"},{"issue":"12","key":"2764_CR17","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1038\/nrneph.2010.122","volume":"6","author":"P Niaudet","year":"2010","unstructured":"Niaudet\u00a0P. Living donor kidney transplantation in patients with hereditary nephropathies. Nat Rev Nephrol. 2010;6(12):736\u201343.","journal-title":"Nat Rev Nephrol"},{"issue":"4","key":"2764_CR18","doi-asserted-by":"publisher","first-page":"597","DOI":"10.2215\/CJN.11220918","volume":"14","author":"KL Lentine","year":"2019","unstructured":"Lentine\u00a0KL, Lam\u00a0NN, Segev\u00a0DL. Risks of Living Kidney Donation: Current State of Knowledge on Outcomes Important to Donors. Clin J Am Soc Nephrol. 2019;14(4):597\u2013608.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"2764_CR19","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1681\/ASN.2016050571","volume":"28","author":"KL Lentine","year":"2017","unstructured":"Lentine\u00a0KL, Segev\u00a0DL. Understanding and Communicating Medical Risks for Living Kidney Donors: A Matter of Perspective. J\u00a0Am Soc Nephrol. 2017;28(1):12\u201324.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"2764_CR20","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1097\/00007890-199803150-00001","volume":"65","author":"FL Delmonico","year":"1998","unstructured":"Delmonico\u00a0FL, Snydman\u00a0DR. Organ donor screening for infectious diseases: review of practice and implications for transplantation. Transplantation. 1998;65(5):603\u201310.","journal-title":"Transplantation"},{"issue":"5","key":"2764_CR21","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/S0272-6386(98)70135-0","volume":"32","author":"DF O\u2019Dea","year":"1998","unstructured":"O\u2019Dea\u00a0DF, Murphy\u00a0SW, Hefferton\u00a0D, et\u00a0al. Higher risk for renal failure in first-degree relatives of white patients with end-stage renal disease: a population-based study. Am J Kidney Dis. 1998;32(5):794\u2013801.","journal-title":"Am J Kidney Dis"},{"issue":"19","key":"2764_CR22","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","volume":"385","author":"LA Inker","year":"2021","unstructured":"Inker\u00a0LA, Eneanya\u00a0ND, Coresh\u00a0J, et\u00a0al. New Creatinine- and Cystatin C\u2011Based Equations to Estimate GFR without Race. N\u00a0Engl J Med. 2021;385(19):1737\u201349.","journal-title":"N Engl J Med"},{"issue":"10","key":"2764_CR23","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1111\/ajt.14713","volume":"18","author":"OA Sanchez","year":"2018","unstructured":"Sanchez\u00a0OA, Ferrara\u00a0LK, Rein\u00a0S, et\u00a0al. Hypertension after kidney donation: Incidence, predictors, and correlates. Am J Transplant. 2018;18(10):2534\u201343.","journal-title":"Am J Transplant"},{"issue":"5","key":"2764_CR24","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1111\/ajt.16384","volume":"21","author":"P Munch","year":"2021","unstructured":"Munch\u00a0P, Christiansen\u00a0CF, Birn\u00a0H, et\u00a0al. Is the risk of cardiovascular disease increased in living kidney donors? A Danish population-based cohort study. Am J Transplant. 2021;21(5):1857\u201365.","journal-title":"Am J Transplant"},{"issue":"3","key":"2764_CR25","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.transproceed.2017.01.012","volume":"49","author":"S Karakose","year":"2017","unstructured":"Karakose\u00a0S, Erdogmus\u00a0S, Akturk\u00a0S, et\u00a0al. Is There a Long-Term Risk for Donors With Heterozygous MEFV Mutation After Kidney Donation. Transplant Proc. 2017;49(3):399\u2013402.","journal-title":"Transplant Proc"},{"issue":"1","key":"2764_CR26","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/ki.2013.460","volume":"86","author":"G Mj\u00f8en","year":"2014","unstructured":"Mj\u00f8en\u00a0G, Hallan\u00a0S, Hartmann\u00a0A, et\u00a0al. Long-term risks for kidney donors. Kidney Int. 2014;86(1):162\u20137.","journal-title":"Kidney Int"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-026-02764-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-026-02764-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-026-02764-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T05:53:40Z","timestamp":1786082020000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-026-02764-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":26,"alternative-id":["2764"],"URL":"https:\/\/doi.org\/10.1007\/s00508-026-02764-2","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]},"assertion":[{"value":"23 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Outside the submitted work, S.\u00a0Mirioglu received support for meeting registration and travel from Amgen and Sanofi Genzyme. O.A.\u00a0Oto, T.E.\u00a0Ozler, A.\u00a0Velioglu, D.B.\u00a0Atas, G.\u00a0Kumru, A.\u00a0Yildiz, S.\u00a0Ozkurt, R.H.\u00a0Hocaoglu, Y.\u00a0Tahillioglu, M.\u00a0Doksan, V.\u00a0Suleymanova, Z.\u00a0Celebi, A.S.\u00a0Artan, A.B.\u00a0Dirim, H.\u00a0Yazici, K.L.\u00a0Lentine and Y.\u00a0Caliskan declare that they have no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants agreed to participate by signing the corresponding informed consent form.","order":2,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was authorized by Istanbul University Ethical Committee (approval number:\u00a0727087) and was conducted in accordance with the ethical principles of the Declaration of Helsinki and data protection regulations.","order":3,"name":"Ethics","label":"Ethical standards","group":{"name":"EthicsHeading","label":"Declarations"}}]}}